Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for ROP Stage 3 Plus
NCT02164604Completed
- Sponsor
- Kantonsspital Aarau
- Start
- Jan 2011
- Primary completion
- Oct 2013
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of ranibizumab in retinopathy of prematurity (ROP), sponsored by Kantonsspital Aarau. Primary endpoint: Number of eyes with ocular side effects due to intravitreal ranibizumab at 6 months. Started Jan 2011; status: completed.
02
Drugs
ranibizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT02164604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02164604.